Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Edesa Biotech Inc

EDSA ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$4.73

▲ +0.00%

Market Cap $63.87M · Vol 17.57K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$63.87M

Micro Cap

Div Yield

N/A

EPS Growth

-56.43%

YoY

RSI (14)

30.40

Momentum

Beta

1.21

vs Market

52W High

$20.20

76.58% below

52W Low

$0.72

556.94% above

Volume

17.57K

Avg 17.76K

P/B

5.53

Price-to-book

ROE

N/A

Return on equity

Free Float

82.33%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Edesa Biotech Inc (EDSA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does EDSA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.11%

-10.25%

-11.92%

-27.45%

YTD

+226.21%

+95.45%

-22.69%

-88.43%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-7,185,520.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-82.85% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	5.53
P/FCF	N/A
EPS Growth	-56.43%
Outstanding Shares	13.50M

Technical Indicators

50-Day SMA	$5.72
200-Day SMA	$5.30
RSI (14)	30.40
Beta	1.21
52-Week High	$20.20
52-Week Low	$0.72

Volume Today	17.57K
Avg Daily Volume (30D)	17.76K
Relative Volume	0.99x
Volatility (10D)	63.98
Volatility (30D)	83.04
Free Float	82.33%

Analyst Consensus

BUY

Current Price $4.73

Mean Target $13.50

52W Low$0.72 52W High$20.20

Current

Target

$0.72 $20.20

Current Analyst target

+185.41% upside potential · 3 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SPM284

ISINCA27966L3065

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateDec 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.57% ARGX.BR argenx SE -0.41% ARGX argenx SE -2.52% INSM Insmed Inc -1.11% 2269.HK WuXi Biologics (Cayman) Inc -3.00%

Company Profile

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.